

Neovii & Fosun Pharma ink agreement for bringing transplantation medicine to China

13 September 2022 | News

For development and commercialization for Grafalon- a rabbit anti-human T-lymphocyte globulin



Neovii Pharmaceuticals, a Swiss based global specialty-care biopharmaceutical company, and Shanghai Fosun Pharmaceutical have entered into an exclusive agreement, under which Neovii has granted Fosun Pharma Industry an exclusive license to develop and commercialize Neovii's Grafalon (rabbit anti-human T-lymphocyte globulin, ATLG) in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.

Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon to Fosun Pharma Industry.

The parties' aim is to firstly strengthen Grafalon's position in the field of transplantation medicine in China, in which it is already approved for marketing and included in China's National Reimbursement Drug List.

Further, the agreement entails clinical development to expand Grafalon's regulatory approval in China to the prevention of Graft versus Host Disease following allogenic stem cell transplantation (SCT), so as to align its approved usages in China with those in Europe and other countries worldwide.

Additional objective is to evolve Grafalon's usages from transplantation medicine to auto-immune and onco-hematology conditions, where Grafalon has the potential to positively-transform the lives of patients suffering from severe diseases with high unmet need.